Skip to main
MDWD

MediWound (MDWD) Stock Forecast & Price Target

MediWound (MDWD) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MediWound is likely to experience significant growth in the near future due to the potential for their partner Vericel to drive upside to consensus outlook and their EscharEx product offering an attractive alternative to market leader Santyl. Additionally, the company's expanded manufacturing facility in Israel is expected to receive regulatory clearance in the second half of 2026, which will support further revenue growth. Management is also optimistic about the company's revenue guidance for FY26, which remains unaffected by regulatory delays and is supported by a growing list of endorsements for their NexoBrid product.

Bears say

MediWound is facing potential delays in its EscharEx Phase 3 VALUE trial, with added patients likely extending timelines by ~4 months and adding $6M in expenses. The company also reported lower than expected revenues for 1Q26 and maintained a net loss, which could impact future financials and hinder the development of its pipeline products. Additionally, there are various risks, including clinical, regulatory, and financial, that could affect the achievement of the company's price target and success of its products.

MediWound (MDWD) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MediWound and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MediWound (MDWD) Forecast

Analysts have given MediWound (MDWD) a Buy based on their latest research and market trends.

According to 2 analysts, MediWound (MDWD) has a Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MediWound (MDWD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.